Aidoc Raises $150 Mn to Expand AI Imaging Platform & Clinical Workflows

The round was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, NVIDIA’s venture capital arm.

Aidoc, a clinical artificial intelligence (AI) company, has raised $150 million in a Series E funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, the venture capital arm of NVIDIA.

The latest round brings Aidoc’s total funding to over $500 million, less than a year after its previous growth round led by General Catalyst and Square Peg. The funding comes amid rising demand for enterprise-scale AI solutions in healthcare systems.

Diagnostic errors and delays contribute to at least 400,000 deaths annually in the United States, driven by increasing imaging volumes, workforce shortages, and growing clinical complexity. While AI adoption has expanded, most tools have historically focused on single-use cases, limiting system-wide impact.

Aidoc has developed a clinical foundation model, CARE™, designed to support broader diagnostic coverage across multiple conditions and imaging modalities. The model is deployed through the company’s enterprise platform, aiOS™, which enables centralized management of AI tools across healthcare systems.

Earlier this year, CARE received FDA clearance for a foundation model-based triage system in clinical imaging. The company reports that its technology currently analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals globally.

"By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error," said Elad Walach, co-founder and CEO of Aidoc. "We feel a deep responsibility to deploy CARE safely and at scale across health systems. This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow, including pixel to draft report within two years."

The company said the new funding will support the expansion of its CARE foundation model, the development of additional clinical applications, and new capabilities, including automated imaging draft report generation.

"Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved," said Christian Resch, Partner at Growth Equity at Goldman Sachs Alternatives. "Health systems consistently describe tangible results, including improved radiology efficiency, shorter lengths of stay, and measurable financial returns. We believe this combination of innovation, safety, technical rigor, and operational discipline positions Aidoc as a long-term leader in clinical AI."

The investment will also support broader global deployment of the aiOS platform as healthcare systems adopt centralized frameworks to manage and scale AI technologies.

Stay tuned for more such updates on Digital Health News